Emmanuelle Vincent1, Susan Todd, John Whitehead
1Pfizer Global Research and Development, Fresnes Laboratories, France. emmanuelle.vincent@pfizer.com
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
This study introduces a novel clinical trial procedure allowing early stopping if an experimental treatment proves superior to control. This method ensures overall error probabilities are controlled during interim analyses for treatments like riluzole in motor neurone disease.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: